thalidomide has been researched along with Chromosomal Translocation in 21 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) can be safely administered to patients with end-stage relapsed/refractory multiple myeloma (RRMM)." | 9.20 | Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. ( Arnulf, B; Attal, M; Avet-Loiseau, H; Banos, A; Benboubker, L; Brechiniac, S; Caillot, D; Decaux, O; Dib, M; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fuzibet, JG; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Lacotte, L; Legros, L; Leleu, X; Macro, M; Marit, G; Mathiot, C; Moreau, P; Onraed, B; Pegourie, B; Petillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Tiab, M; Wetterwald, M, 2015) |
| "A 61-year-old man, who was diagnosed with Bence-Jones protein (BJP)-λ type multiple myeloma, was treated with bortezomib." | 7.79 | [The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide]. ( Arakaki, H; Uchihara, JN, 2013) |
| "In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM)." | 7.77 | Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. ( Goldschmidt, H; Hielscher, T; Hillengass, J; Ho, AD; Hose, D; Jauch, A; Klein, U; Neben, K; Raab, MS; Seckinger, A, 2011) |
| "The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) can be safely administered to patients with end-stage relapsed/refractory multiple myeloma (RRMM)." | 5.20 | Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. ( Arnulf, B; Attal, M; Avet-Loiseau, H; Banos, A; Benboubker, L; Brechiniac, S; Caillot, D; Decaux, O; Dib, M; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fuzibet, JG; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Lacotte, L; Legros, L; Leleu, X; Macro, M; Marit, G; Mathiot, C; Moreau, P; Onraed, B; Pegourie, B; Petillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Tiab, M; Wetterwald, M, 2015) |
| "Mantle cell lymphoma (MCL), which accounts for about 6% of non-Hodgkin lymphoma (NHL), is characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in de-regulated expression of cyclin D1." | 4.89 | Therapies for mantle cell lymphoma: current challenges and a brighter future. ( Skarbnik, AP; Smith, MR, 2013) |
| "The introduction of thalidomide, bortezomib and lenalidomide has dramatically changed the treatment paradigm of multiple myeloma (MM)." | 4.85 | Treatment of newly diagnosed myeloma. ( Palumbo, A; Rajkumar, SV, 2009) |
| "A 61-year-old man, who was diagnosed with Bence-Jones protein (BJP)-λ type multiple myeloma, was treated with bortezomib." | 3.79 | [The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide]. ( Arakaki, H; Uchihara, JN, 2013) |
| "In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM)." | 3.77 | Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. ( Goldschmidt, H; Hielscher, T; Hillengass, J; Ho, AD; Hose, D; Jauch, A; Klein, U; Neben, K; Raab, MS; Seckinger, A, 2011) |
| "We report the cases of 3 patients with hematological malignancies and complex karyotypes involving der(5; 17) (p10;q10), which results in the loss of 5q and 17p." | 2.50 | der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. ( Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T, 2014) |
| "Multiple myeloma is a malignancy of antibody-secreting plasma cells." | 1.51 | Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. ( Auclair, D; Bahlis, NJ; Barwick, BG; Boise, LH; Dhodapkar, MV; Gupta, VA; Hofmeister, CC; Jaye, DL; Kaufman, JL; Keats, JJ; Lonial, S; Neri, P; Nooka, AK; Vertino, PM, 2019) |
| "Thalidomide treatment was associated with significant down-regulation of nuclear NF-κB expression levels in residual neoplastic cells and microenvironments of responsive tumors, but not in t(11;18)(q21;q21)-positive, thalidomide-refractory tumors." | 1.37 | t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. ( Chen, LT; Cheng, AL; Hsu, CH; Kuo, SH; Lin, CW; Tzeng, YS; Wu, MS; Yeh, KH, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 18 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barwick, BG | 1 |
| Neri, P | 1 |
| Bahlis, NJ | 1 |
| Nooka, AK | 1 |
| Dhodapkar, MV | 1 |
| Jaye, DL | 1 |
| Hofmeister, CC | 1 |
| Kaufman, JL | 1 |
| Gupta, VA | 1 |
| Auclair, D | 1 |
| Keats, JJ | 1 |
| Lonial, S | 1 |
| Vertino, PM | 1 |
| Boise, LH | 1 |
| Rajkumar, SV | 4 |
| Skarbnik, AP | 1 |
| Smith, MR | 1 |
| Uchihara, JN | 1 |
| Arakaki, H | 1 |
| Manabe, M | 1 |
| Okita, J | 1 |
| Tarakuwa, T | 1 |
| Harada, N | 1 |
| Aoyama, Y | 1 |
| Kumura, T | 1 |
| Ohta, T | 1 |
| Furukawa, Y | 1 |
| Mugitani, A | 1 |
| Bianchi, G | 1 |
| Richardson, PG | 1 |
| Anderson, KC | 1 |
| Vincent Rajkumar, S | 1 |
| Leleu, X | 1 |
| Karlin, L | 1 |
| Macro, M | 1 |
| Hulin, C | 1 |
| Garderet, L | 1 |
| Roussel, M | 1 |
| Arnulf, B | 1 |
| Pegourie, B | 1 |
| Kolb, B | 1 |
| Stoppa, AM | 1 |
| Brechiniac, S | 1 |
| Marit, G | 1 |
| Thielemans, B | 1 |
| Onraed, B | 1 |
| Mathiot, C | 1 |
| Banos, A | 1 |
| Lacotte, L | 1 |
| Tiab, M | 1 |
| Dib, M | 1 |
| Fuzibet, JG | 1 |
| Petillon, MO | 1 |
| Rodon, P | 1 |
| Wetterwald, M | 1 |
| Royer, B | 1 |
| Legros, L | 1 |
| Benboubker, L | 1 |
| Decaux, O | 1 |
| Escoffre-Barbe, M | 1 |
| Caillot, D | 1 |
| Fermand, JP | 1 |
| Moreau, P | 1 |
| Attal, M | 1 |
| Avet-Loiseau, H | 1 |
| Facon, T | 1 |
| Kaufman, GP | 1 |
| Gertz, MA | 1 |
| Dispenzieri, A | 1 |
| Lacy, MQ | 1 |
| Buadi, FK | 1 |
| Dingli, D | 1 |
| Hayman, SR | 1 |
| Kapoor, P | 1 |
| Lust, JA | 1 |
| Russell, S | 1 |
| Go, RS | 1 |
| Hwa, YL | 1 |
| Kyle, RA | 2 |
| Kumar, SK | 1 |
| Ureshino, H | 1 |
| Kizuka, H | 1 |
| Kusaba, K | 1 |
| Sano, H | 1 |
| Nishioka, A | 1 |
| Shindo, T | 1 |
| Kubota, Y | 1 |
| Ando, T | 1 |
| Kojima, K | 1 |
| Kimura, S | 1 |
| Palumbo, A | 1 |
| Sugiyama, A | 1 |
| Nakabayashi, H | 1 |
| Kondo, M | 1 |
| Tominaga, T | 1 |
| Shinohara, K | 1 |
| Yuan, J | 1 |
| Shah, R | 1 |
| Kulharya, A | 1 |
| Ustun, C | 1 |
| Kuo, SH | 1 |
| Cheng, AL | 1 |
| Lin, CW | 1 |
| Hsu, CH | 1 |
| Wu, MS | 1 |
| Yeh, KH | 1 |
| Tzeng, YS | 1 |
| Chen, LT | 1 |
| Klein, U | 1 |
| Jauch, A | 1 |
| Hielscher, T | 1 |
| Hillengass, J | 1 |
| Raab, MS | 1 |
| Seckinger, A | 1 |
| Hose, D | 1 |
| Ho, AD | 1 |
| Goldschmidt, H | 1 |
| Neben, K | 1 |
| Ho, PJ | 1 |
| Brown, RD | 1 |
| Spencer, A | 1 |
| Jeffels, M | 1 |
| Daniher, D | 1 |
| Gibson, J | 1 |
| Joshua, DE | 1 |
| Grzasko, N | 1 |
| Hus, M | 1 |
| Chocholska, S | 1 |
| Pluta, A | 1 |
| Hajek, R | 1 |
| Dmoszynska, A | 1 |
| Locke, FL | 1 |
| Morgan, GJ | 2 |
| Zhang, M | 1 |
| You, Y | 1 |
| Li, X | 1 |
| He, Y | 1 |
| Zheng, J | 1 |
| Li, W | 1 |
| Zou, P | 1 |
| Liu, X | 1 |
| Liu, F | 1 |
| Brioli, A | 1 |
| Kaiser, MF | 1 |
| Pawlyn, C | 1 |
| Wu, P | 1 |
| Gregory, WM | 1 |
| Owen, R | 1 |
| Ross, FM | 1 |
| Jackson, GH | 1 |
| Cavo, M | 1 |
| Davies, FE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic[NCT03683277] | Phase 2 | 26 participants (Actual) | Interventional | 2019-11-03 | Terminated (stopped due to Recruitment issue, 26 patients enrolled instead of 70 initially planned) | ||
| A Multicenter Open Label Phase II Study of Pomalidomide and Dexamethasone in Progressive Relapsed or Refractory Multiple Myeloma Patients With Deletion 17p or Translocation (4;14) Adverse Karyotypic Abnormalities-IFM2010-02[NCT01745640] | Phase 2 | 63 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study[NCT01675141] | Phase 2 | 11 participants (Actual) | Interventional | 2012-08-20 | Terminated (stopped due to Original investigator left the NIH and the primary outcome was not reached) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of response is defined as time from response to disease progression or death. Progression is assessed by the International Myeloma Workshop Consensus Panel Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from baseline or lowest response value in Serum M component, Urine M component, free light chain or bone marrow plasma cell percentage. Lowest response value does not need to be a confirmed value. Serum M-component absolute increase must be ≥0.5 g/dl. The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥5 g/dl. Urine M-component absolute increase must be ≥200mg/24h. Only in patients without measureable serum and urine M-protein levels: the absolute increase in difference between involved and uninvolved free light chain levels must be >10mg/dl. (NCT01675141)
Timeframe: participants were followed for the duration of their treatment, an average of 2 years
| Intervention | Months (Median) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | NA |
Here is the number of serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01675141)
Timeframe: 37 months and 12 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | 11 |
PFS is defined as the time from study entry until progression or death. Progression is assessed by the International Myeloma Workshop Consensus Panel Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from baseline or lowest response value in Serum M component, Urine M component, free light chain or bone marrow plasma cell percentage. Lowest response value does not need to be a confirmed value. Serum M-component absolute increase must be ≥0.5 g/dl. The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥5 g/dl. Urine M-component absolute increase must be ≥200mg/24h. Only in patients without measureable serum and urine M-protein levels: the absolute increase in difference between involved and uninvolved free light chain levels must be >10mg/dl. (NCT01675141)
Timeframe: participants were followed for the duration of their treatment, an average of 2 years
| Intervention | months (Median) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | NA |
7 reviews available for thalidomide and Chromosomal Translocation
| Article | Year |
|---|---|
Therapies for mantle cell lymphoma: current challenges and a brighter future.
Topics: Antibodies; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Cyclin D1; E | 2013 |
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combi | 2014 |
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; Cyclo | 2014 |
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromo | 2017 |
Treatment of newly diagnosed myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bo | 2009 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; H | 2012 |
Multiple myeloma: diagnosis and treatment.
Topics: Algorithms; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Dexametha | 2005 |
2 trials available for thalidomide and Chromosomal Translocation
| Article | Year |
|---|---|
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, | 2015 |
Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; C | 2012 |
12 other studies available for thalidomide and Chromosomal Translocation
| Article | Year |
|---|---|
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Topics: Antineoplastic Agents; DNA Copy Number Variations; Drug Resistance, Neoplasm; Enhancer Elements, Gen | 2019 |
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamet | 2013 |
[The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide].
Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 22; Chromosomes, Human, Pai | 2013 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; | 2014 |
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosomes, Human, Pair 11 | 2016 |
[Multiple myeloma with variant type translocation, t(8;22)(q24;q11.2)].
Topics: Administration, Oral; Aged; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Dexamethasone; | 2009 |
Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boro | 2010 |
t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement.
Topics: Aged; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 18; Disease-Free Survival; Female; Human | 2011 |
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberratio | 2011 |
1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberratio | 2012 |
Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Adult; Anemia, Refractory; Bone Marrow; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 3; Fema | 2013 |
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.
Topics: Aged; Female; Humans; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Maintenance Che | 2013 |